Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing

Dr. Joel Warsh

👤 Person
798 total appearances

Appearances Over Time

Podcast Appearances

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

Exactly. And then when they both have the same profile of issues, so let's say you test Advil versus Aleve.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

Exactly. And then when they both have the same profile of issues, so let's say you test Advil versus Aleve.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

Right. Let's say that you get three seizures in that study. Okay. They say, well, there were three seizures in both groups, so there's no concerns. But if you studied against water, you had zero seizures, there would be a difference there. And that's not the way things are done. And we're in this weird place now because of ethics, right?

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

Right. Let's say that you get three seizures in that study. Okay. They say, well, there were three seizures in both groups, so there's no concerns. But if you studied against water, you had zero seizures, there would be a difference there. And that's not the way things are done. And we're in this weird place now because of ethics, right?

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

Right. Let's say that you get three seizures in that study. Okay. They say, well, there were three seizures in both groups, so there's no concerns. But if you studied against water, you had zero seizures, there would be a difference there. And that's not the way things are done. And we're in this weird place now because of ethics, right?

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

where it's hard to do a study against unvaccinated kids when you have a vaccine that's already on the market because there's an ethics there around not giving the standard of care. And so because they weren't done correctly or the best way in the beginning, now we're in this catch because we have all these vaccines on the market.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

where it's hard to do a study against unvaccinated kids when you have a vaccine that's already on the market because there's an ethics there around not giving the standard of care. And so because they weren't done correctly or the best way in the beginning, now we're in this catch because we have all these vaccines on the market.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

where it's hard to do a study against unvaccinated kids when you have a vaccine that's already on the market because there's an ethics there around not giving the standard of care. And so because they weren't done correctly or the best way in the beginning, now we're in this catch because we have all these vaccines on the market.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

If we want to restudy them, how do we do that in a way where we can get a baseline? makes it really tough.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

If we want to restudy them, how do we do that in a way where we can get a baseline? makes it really tough.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

If we want to restudy them, how do we do that in a way where we can get a baseline? makes it really tough.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

But we should acknowledge this. So if we do bring something new on the market, then we can increase those standards. Say we need you to do a study against an inert placebo for a new product, like the Prevnar vaccine, the original study. There were no other Prevnars on the market. They studied against the meningitis vaccine. That makes no sense.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

But we should acknowledge this. So if we do bring something new on the market, then we can increase those standards. Say we need you to do a study against an inert placebo for a new product, like the Prevnar vaccine, the original study. There were no other Prevnars on the market. They studied against the meningitis vaccine. That makes no sense.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

But we should acknowledge this. So if we do bring something new on the market, then we can increase those standards. Say we need you to do a study against an inert placebo for a new product, like the Prevnar vaccine, the original study. There were no other Prevnars on the market. They studied against the meningitis vaccine. That makes no sense.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

They could study it against free solution, water, but they studied against meningitis. That's

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

They could study it against free solution, water, but they studied against meningitis. That's

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

They could study it against free solution, water, but they studied against meningitis. That's

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

There's no reason that you should approve that. They should require them to have a third group that's also saltwater. There's no logical reason you wouldn't do it unless you don't want to take the chance to show what the difference is between that and saltwater. And you may find the exact same thing, but we should require that.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

There's no reason that you should approve that. They should require them to have a third group that's also saltwater. There's no logical reason you wouldn't do it unless you don't want to take the chance to show what the difference is between that and saltwater. And you may find the exact same thing, but we should require that.

The Dr. Hyman Show
Why Vaccine Safety Is So Hard to Talk About — with Dr. Joel Warsh

There's no reason that you should approve that. They should require them to have a third group that's also saltwater. There's no logical reason you wouldn't do it unless you don't want to take the chance to show what the difference is between that and saltwater. And you may find the exact same thing, but we should require that.